Correcting the Record: Addressing The New York Times’ Deceptive Coverage of Psymposia
Rather than unpacking the actual causes of Lykos Therapeutics' disastrous Phase 3 trials and FDA rejection, The New York Times produced a work of fictitious propaganda that prioritizes corporate interests over public health. The post Correcting the Record: Addressing The New York Times’ Deceptive Coverage of Psymposia appeared first on Psymposia.
External link. We are not responsible for the content.
Read more ↗More From Psymposia
Hamilton’s Pharma Cope, Part 4: “The Face of Psychedelic Journalistic Ethics” Transcript
In this episode, we continue the conversation about our funding and explore Hamilton Morris' conspiratorial claims ab...
Hamilton’s Pharma Cope, Part 3: Paid Protestor Paranoia Transcript
In this episode, we continue the conversation about our funding and explore Hamilton Morris' conspiratorial claims ab...
Latest News
Psychedelic Policy Briefing: Week of July 13th, 2026
Massachusetts advances a psychedelic therapy pilot program, the FDA finalizes its psychedelic trial guidance and sets...
The Rush for Iboga Looks Different from Gabon
Gabonese civil servant and environmental lawyer Georges Gassita on what the ibogaine rush looks like from inside Gabo...
The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet
The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psy...
Do people hear voices when they take ayahuasca? 5 Questions with social anthropologist David Dupuis
Dupuis discusses how auditory hallucinations during psychedelic trips have been overlooked.
One of Psychedelia’s Most Notorious Gurus Is Officially Put on Blast
PLUS, stories about datura, the Huni Kuin, and Oregon's drug policy programs. [...] Read More... The post One of Psyc...
LSD Just Joined The Establishment
This Week’s Sunday Insider: The most anti-establishment Psychedelic in history is becoming part of the establishment.